Aiforia expands to nine hospitals in Spain
Summary
- Aiforia announced its selection as a provider of AI-assisted diagnostic solutions to a regional health service provider in Spain, covering nine hospitals with applications for breast and prostate cancer.
- The partnership with Palex, which won the public tender, allows Aiforia to scale growth efficiently without a large in-house sales team, leveraging a significant regional network.
- The Spanish deal aligns with Aiforia's strategy to expand in the clinical diagnostics market, contributing to a projected 45% revenue growth to 5.1 MEUR for the full year 2026.
- The agreement is expected to enhance recurring revenue and demonstrates the company's competitiveness in the evolving pathology market.
This content is generated by AI. You can give feedback on it in the Inderes forum.
Translation: Original published in Finnish on 06/12/2026 at 08:08 am EEST
Aiforia announced on Thursday that it has been selected as a provider of AI-assisted diagnostic solutions to a regional health service provider in Spain. The agreement covers nine hospitals, which will be supplied with AI applications for breast and prostate cancer. The news is a continuation of the company's positive development in terms of new customer wins. We are not making changes to our estimates based on the news, as we already expect strong revenue growth from the company in the coming years.
Partnership strategy proves its viability
Aiforia's Spanish medical technology partner, Palex, won the public tender. We find it beneficial for Aiforia to leverage partnerships to scale its growth and reach a broad customer base without a heavy in-house sales organization. We consider the regional network of nine hospitals to be significant in size, and breast and prostate cancer diagnostics represent high volumes in clinical pathology. We believe the agreement will create a strong foundation for the expanded use of the software and increased recurring revenue in the future.
The clinical segment acts as a growth engine
Aiforia's investment case relies heavily on the opening of the clinical diagnostics market and the company's ability to win new customers. The Spanish deal is a logical continuation of the company's recent clinical customer wins in Europe. While individual customers rarely change the big picture or short-term estimates immediately, they build an important reference base and critical mass for the company. We expect Aiforia's full-year 2026 revenue to grow by 45% to 5.1 MEUR. The latest customer win further strengthens our confidence that the company's competitiveness is at a good level and that the conservative pathology market is gradually maturing towards routine use of AI solutions.
Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.
Read more on company pageKey Estimate Figures08.03
| 2025 | 26e | 27e | |
|---|---|---|---|
| Revenue | 3.5 | 5.1 | 7.9 |
| growth-% | 24.0 % | 45.0 % | 55.0 % |
| EBIT (adj.) | -11.2 | -9.2 | -8.3 |
| EBIT-% (adj.) | -316.3 % | -178.7 % | -104.7 % |
| EPS (adj.) | -0.38 | -0.25 | -0.19 |
| Dividend | 0.00 | 0.00 | 0.00 |
| Dividend % | |||
| P/E (adj.) | neg. | neg. | neg. |
| EV/EBITDA | neg. | neg. | neg. |
Forum discussions
